Insider Transactions in Q1 2025 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 27
2025
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
50,000
+4.0%
|
$2,150,000
$43.55 P/Share
|
|
Mar 26
2025
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
58,691
+4.86%
|
$2,523,713
$43.01 P/Share
|
|
Mar 25
2025
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
91,309
+7.72%
|
$4,017,596
$44.75 P/Share
|
|
Mar 17
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.83%
|
$440,000
$44.88 P/Share
|
|
Mar 17
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.69%
|
$210,000
$21.1 P/Share
|
|
Mar 12
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
1,738
-0.26%
|
$76,472
$44.88 P/Share
|
|
Mar 12
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
614
-0.64%
|
$27,016
$44.88 P/Share
|
|
Mar 12
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
607
-0.3%
|
$26,708
$44.88 P/Share
|
|
Mar 12
2025
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
676
-1.08%
|
$29,744
$44.88 P/Share
|
|
Mar 12
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
516
-0.3%
|
$22,704
$44.88 P/Share
|
|
Mar 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-2.19%
|
$1,260,000
$42.03 P/Share
|
|
Mar 05
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,500
-3.47%
|
$550,000
$44.65 P/Share
|
|
Mar 05
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+6.4%
|
$262,500
$21.1 P/Share
|
|
Mar 04
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
50,000
-10.32%
|
$2,200,000
$44.62 P/Share
|
|
Mar 03
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
1,000
-2.9%
|
$48,000
$48.09 P/Share
|
|
Mar 03
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+2.82%
|
$19,000
$19.87 P/Share
|
|
Feb 18
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.77%
|
$500,000
$50.21 P/Share
|
|
Feb 18
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.65%
|
$210,000
$21.1 P/Share
|
|
Feb 10
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-0.85%
|
$1,590,000
$53.74 P/Share
|
|
Feb 05
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
18,750
-5.07%
|
$1,050,000
$56.63 P/Share
|
|
Feb 05
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+9.03%
|
$393,750
$21.1 P/Share
|
|
Feb 03
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-1.93%
|
$530,000
$53.81 P/Share
|
|
Jan 30
2025
|
G. Walmsley Graham |
BUY
Open market or private purchase
|
Indirect |
200,000
+16.67%
|
$9,600,000
$48.0 P/Share
|
|
Jan 27
2025
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
102,664
-13.17%
|
$5,749,184
$56.04 P/Share
|
|
Jan 27
2025
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
102,664
+15.4%
|
$1,231,968
$12.29 P/Share
|
|
Jan 27
2025
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-1.35%
|
$1,650,000
$55.66 P/Share
|
|
Jan 27
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
SELL
Open market or private sale
|
Direct |
5,000
-12.99%
|
$285,000
$57.03 P/Share
|
|
Jan 27
2025
|
Patrick Lamy Senior VP, Commercial Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+9.41%
|
$76,000
$19.87 P/Share
|
|
Jan 27
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
31,250
-5.44%
|
$1,718,750
$55.78 P/Share
|
|
Jan 27
2025
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+7.48%
|
$625,000
$20.49 P/Share
|
|
Jan 24
2025
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,064
+14.16%
|
$258,384
$6.36 P/Share
|
|
Jan 23
2025
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+6.28%
|
$0
$0.62 P/Share
|
|
Jan 07
2025
|
Timothy Rolph Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
14,000
-7.6%
|
-
|
|
Jan 02
2025
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.38%
|
$280,000
$28.03 P/Share
|